SOUTH SAN FRANCISCO, Calif., July 5, 2024 /PRNewswire/ — IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medication oncology firm dedicated to the invention and growth of focused therapeutics, at present introduced that the corporate plans to challenge a pre-market press launch and conduct an investor webcast on Monday, July 8, 2024, at 8:00 a.m. EST to supply a medical information replace for the IDE397 Part 2 monotherapy enlargement dose in MTAP-deletion urothelial and non-small cell lung most cancers (NSCLC) sufferers. IDE397 is a potent and selective potential first-in-class methionine adenosyltransferase 2 alpha (MAT2A) inhibitor in Part 2 medical trials for the therapy of methylthioadenosine phosphorylase (MTAP) deletion stable tumors.
The investor webcast presentation agenda to assessment the IDE397 medical information replace of the Part 2 enlargement dose ends in MTAP-deletion urothelial and NSCLC sufferers would be the following:
-
Market introduction: U.S. annual incidence in MTAP-deletion stable tumors
-
IDE397 preclinical abstract in MTAP-deletion
-
Affected person baseline traits
-
Pharmacokinetics and pharmacodynamics
-
Hostile occasion profile
-
Scientific efficacy in 18 evaluable MTAP-deletion urothelial and NSCLC sufferers by RECIST 1.1
-
Total Response Fee (%ORR) and Illness Management Fee (%DCR) evaluation
-
Swimlane plot
-
ctDNA molecular response evaluation
-
Case studies and CT-scan photos
-
The IDEAYA audio system will embrace Yujiro S. Hata, Chief Government Officer, Darrin Beaupre, M.D., Ph.D., Chief Medical Officer, and Michael White, Ph.D., Chief Scientific Officer. The hyperlink to the investor webcast will probably be obtainable on the Investor Relations Occasions part of the Firm’s web site at: https://ir.ideayabio.com/occasions. Registration is out there at https://ir.ideayabio.com/occasions or https://lifescievents.com/occasion/ideaya-2/ upfront of the occasion.
IDEAYA’s IDE397 investor webcast presentation, in addition to an up to date company presentation, which is able to incorporate the up to date IDE397 medical information, will probably be obtainable on the corporate’s web site, at its Investor Relations portal (https://ir.ideayabio.com/) at roughly 8:00 am ET on Monday, July 8, 2024.
There may be an ongoing Part 2 enlargement of IDE397 monotherapy in MTAP-deletion stable tumors (NCT04794699), and an Amgen-sponsored Part 1/2 trial of IDE397 and Amgen’s investigational MTA-cooperative protein arginine methytranferase 5 inhibitor AMG 193 mixture in MTAP-deletion NSCLC (NCT05975073) for which the businesses intend to develop a joint publication technique in 2024. As well as, IDEAYA has initiated enrollment in a Part 1 medical trial evaluating the protection, tolerability, pharmacokinetics, pharmacodynamics and efficacy of IDE397 together with Gilead’s Trop-2 directed anti-body conjugate Trodelvy (NCT04794699). IDEAYA can be advancing a number of preclinical stage MTAP-deletion packages to allow wholly-owned combos with IDE397, together with a program concentrating on a growth candidate nomination within the second half of 2024.
About IDEAYA Biosciences
IDEAYA is a precision medication oncology firm dedicated to the invention and growth of focused therapeutics for affected person populations chosen utilizing molecular diagnostics. IDEAYA’s method integrates capabilities in figuring out and validating translational biomarkers with drug discovery to pick affected person populations almost definitely to learn from its focused therapies. IDEAYA is making use of its analysis and drug discovery capabilities to artificial lethality – which represents an rising class of precision medication targets.
Ahead-Trying Statements
This press launch accommodates forward-looking statements, together with, however not restricted to, statements associated to (i) the timing and content material of the IDE397 medical information replace press launch, investor webcast and investor shows, (ii) the timing for the event of a joint Amgen/IDEAYA publication technique for the Part 1/2 IDE397 and AMG 193 mixture, (iii) the timing of preclinical stage MTAP-deletion packages together with IDE397 and (iv) nomination of an IDE397 mixture growth candidate within the second half of 2024. IDEAYA undertakes no obligation to replace or revise any forward-looking statements. Such forward-looking statements contain substantial dangers and uncertainties. For an extra description of the dangers and uncertainties that might trigger precise occasions and outcomes to vary from these expressed in these forward-looking statements, in addition to dangers referring to the enterprise of IDEAYA on the whole, see IDEAYA’s Annual Report on Kind 10-Okay filed on February 20, 2024, Quarterly Report on Kind 10-Q filed on Could 7, 2024 and any extra present and periodic studies filed with the U.S. Securities and Change Fee.
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
SVP, Head of Finance and Investor Relations
investor@ideayabio.com
View authentic content material to obtain multimedia:https://www.prnewswire.com/news-releases/ideaya-announces-investor-webcast-to-report-clinical-data-update-for-ide397-phase-2-monotherapy-expansion-dose-in-mtap-deletion-urothelial-and-lung-cancer-on-monday-july-8-2024-302190198.html
SOURCE IDEAYA Biosciences, Inc.
